Cargando…

LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data

BACKGROUND: Somatic amplifications of the LYL1 gene are relatively common occurrences in patients who develop uterine corpus endometrial carcinoma (UCEC) as opposed to other cancers. This study was undertaken to determine whether such genetic alterations affect survival outcomes of UCEC. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Se Ik, Lee, Ji Won, Lee, Nara, Lee, Maria, Kim, Hee Seung, Chung, Hyun Hoon, Kim, Jae-Weon, Park, Noh Hyun, Song, Yong-Sang, Seo, Jeong-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930686/
https://www.ncbi.nlm.nih.gov/pubmed/29716549
http://dx.doi.org/10.1186/s12885-018-4429-z
_version_ 1783319521246838784
author Kim, Se Ik
Lee, Ji Won
Lee, Nara
Lee, Maria
Kim, Hee Seung
Chung, Hyun Hoon
Kim, Jae-Weon
Park, Noh Hyun
Song, Yong-Sang
Seo, Jeong-Sun
author_facet Kim, Se Ik
Lee, Ji Won
Lee, Nara
Lee, Maria
Kim, Hee Seung
Chung, Hyun Hoon
Kim, Jae-Weon
Park, Noh Hyun
Song, Yong-Sang
Seo, Jeong-Sun
author_sort Kim, Se Ik
collection PubMed
description BACKGROUND: Somatic amplifications of the LYL1 gene are relatively common occurrences in patients who develop uterine corpus endometrial carcinoma (UCEC) as opposed to other cancers. This study was undertaken to determine whether such genetic alterations affect survival outcomes of UCEC. METHODS: In 370 patients with UCEC, we analysed clinicopathologic characteristics and corresponding genomic data from The Cancer Genome Atlas database. Patients were stratified according to LYL1 gene status, grouped as amplification or non-amplification. Heightened levels of cancer-related genes expressed in concert with LYL1 amplification were similarly investigated through differentially expressed gene and gene set enrichment analyses. Factors associated with survival outcomes were also identified. RESULTS: Somatic LYL1 gene amplification was observed in 22 patients (5.9%) with UCEC. Patients displaying amplification (vs. non-amplification) were significantly older at the time of diagnosis and more often were marked by non-endometrioid, high-grade, or advanced disease. In survival analysis, the amplification subset showed poorer progression-free survival (PFS) and overall survival (OS) rates (3-year PFS: 34.4% vs. 79.9%, P = 0.031; 5-year OS: 25.1% vs. 84.9%, P = 0.014). However, multivariate analyses adjusted for tumor histologic type, grade, and stage did not confirm LYL1 gene amplification as an independent prognostic factor for either PFS or OS. Nevertheless, MAPK, WNT, and cell cycle pathways were significantly enriched by LYL1 gene amplification (P < 0.001, P = 0.002, and P = 0.004, respectively). CONCLUSIONS: Despite not being identified as an independent prognostic factor in UCEC, LYL1 gene amplification is associated with other poor prognostic factors and correlated with upregulation of cancer-related pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4429-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5930686
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59306862018-05-09 LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data Kim, Se Ik Lee, Ji Won Lee, Nara Lee, Maria Kim, Hee Seung Chung, Hyun Hoon Kim, Jae-Weon Park, Noh Hyun Song, Yong-Sang Seo, Jeong-Sun BMC Cancer Research Article BACKGROUND: Somatic amplifications of the LYL1 gene are relatively common occurrences in patients who develop uterine corpus endometrial carcinoma (UCEC) as opposed to other cancers. This study was undertaken to determine whether such genetic alterations affect survival outcomes of UCEC. METHODS: In 370 patients with UCEC, we analysed clinicopathologic characteristics and corresponding genomic data from The Cancer Genome Atlas database. Patients were stratified according to LYL1 gene status, grouped as amplification or non-amplification. Heightened levels of cancer-related genes expressed in concert with LYL1 amplification were similarly investigated through differentially expressed gene and gene set enrichment analyses. Factors associated with survival outcomes were also identified. RESULTS: Somatic LYL1 gene amplification was observed in 22 patients (5.9%) with UCEC. Patients displaying amplification (vs. non-amplification) were significantly older at the time of diagnosis and more often were marked by non-endometrioid, high-grade, or advanced disease. In survival analysis, the amplification subset showed poorer progression-free survival (PFS) and overall survival (OS) rates (3-year PFS: 34.4% vs. 79.9%, P = 0.031; 5-year OS: 25.1% vs. 84.9%, P = 0.014). However, multivariate analyses adjusted for tumor histologic type, grade, and stage did not confirm LYL1 gene amplification as an independent prognostic factor for either PFS or OS. Nevertheless, MAPK, WNT, and cell cycle pathways were significantly enriched by LYL1 gene amplification (P < 0.001, P = 0.002, and P = 0.004, respectively). CONCLUSIONS: Despite not being identified as an independent prognostic factor in UCEC, LYL1 gene amplification is associated with other poor prognostic factors and correlated with upregulation of cancer-related pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4429-z) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-02 /pmc/articles/PMC5930686/ /pubmed/29716549 http://dx.doi.org/10.1186/s12885-018-4429-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kim, Se Ik
Lee, Ji Won
Lee, Nara
Lee, Maria
Kim, Hee Seung
Chung, Hyun Hoon
Kim, Jae-Weon
Park, Noh Hyun
Song, Yong-Sang
Seo, Jeong-Sun
LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data
title LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data
title_full LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data
title_fullStr LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data
title_full_unstemmed LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data
title_short LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data
title_sort lyl1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the cancer genome atlas data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930686/
https://www.ncbi.nlm.nih.gov/pubmed/29716549
http://dx.doi.org/10.1186/s12885-018-4429-z
work_keys_str_mv AT kimseik lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT leejiwon lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT leenara lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT leemaria lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT kimheeseung lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT chunghyunhoon lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT kimjaeweon lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT parknohhyun lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT songyongsang lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata
AT seojeongsun lyl1geneamplificationpredictspoorsurvivalofpatientswithuterinecorpusendometrialcarcinomaanalysisofthecancergenomeatlasdata